Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
Symposium faculty to include Dmitriy Zamarin, MD, PhD, and Alexander N. Shoushtari, MD, medical oncologists from Memorial Sloan Kettering Cancer CenterOslo, Norway, 11 October 2018 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is hosting a Key Opinion Leader (KOL) symposium in New York City today, featuring two renowned immunotherapy experts from the Memorial Sloan Kettering Cancer Center. The meeting will consist of presentations from world leading experts on oncolytic viruses, as well as